Uveal melanoma metastatic at initial diagnosis: a case series

Steckler, Alexa M; Francis, Jasmine H.; Shoushtari, Alexander N.; Abramson, David H.; Barker, Christopher A.

doi:10.1097/cmr.0000000000000807

Cited by 3 publications

(3 citation statements)

References 15 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One patient developed liver metastases as long as 36.7 years after the initial diagnosis of UM. Less than 3% of patients present with metastatic disease at initial diagnosis, which is consistent with our results (4%) 14 …”

Section: Discussionsupporting

confidence: 93%

“…Less than 3% of patients present with metastatic disease at initial diagnosis, which is consistent with our results (4%). 14 Patients with CM had a higher incidence of BRAF mutation (55% vs. 0%, p < 0.001) compared with patients with UM. Tan et al also reported a different BRAF mutant status between UM (8.3%) and CM patients (57.1%) (p = 0.038) in a multi-ethnic Asian cohort.…”

Section: Discussionmentioning

confidence: 88%

“…Less than 3% of patients present with metastatic disease at initial diagnosis, which is consistent with our results (4%). 14 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical features and prognosis of patients with metastatic ocular and orbital melanoma: A bi‐institutional study

et al. 2023

View full text Add to dashboard Cite

PurposeMetastatic ocular and orbital melanomas are extremely rare. The clinical characteristics and standard treatments for these patients are not fully established.Materials and MethodsWe retrospectively analyzed patients with metastatic ocular and orbital melanoma from Fudan University Shanghai Cancer Center and Eye & ENT Hospital of Fudan University between January 2012 and May 2022.ResultsOverall, 51 patients with metastatic ocular and orbital melanoma were included. The most common primary sites were uvea (73%), followed by conjunctiva (22%), lacrimal sac (4%), and orbit (2%). Patients with uveal melanoma (UM) had a significantly younger age (48 vs. 68 years, p < 0.001), higher incidence of liver metastases (89% vs. 9%, p<0.001), a lower incidence of lymph nodes metastases (16% vs. 46%, p = 0.043) and a lower incidence of BRAF mutation (0% vs. 55%, p<0.001) compared with patients with conjunctival melanoma (CM). The overall response rate of the first‐line treatment was 18%. Three of the four patients with BRAF‐mutated CM responded to dabrafenib and trametinib treatment. The median progression‐free survival (PFS) and overall survival (OS) of first‐line treatment were 5.1 and 11.9 months, respectively. Among patients with liver metastases, liver‐directed treatment was correlated with better patient PFS (p < 0.001) and OS (p < 0.001) after adjusting for number of metastatic sites and primary sites.ConclusionCM and UM have different characteristics. Patient with CM had a high incidence of BRAF mutation, and the treatment of BRAF and MEK inhibitors conferred clinical benefit. Liver directed therapies had a potential benefit in disease control in patients with liver metastases.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 88%